OrbiMed’s Cymabay Therapeutics CBAY Stock Holding History

OrbiMed’s Portfolio CBAY Stock Details CBAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,874,955	Closed	-$24.9M	–	139
2019 Q1	$24.9M	Buy	+1,874,955	New	+$19.9M	0.39%	64

Other funds holding CBAY

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

OrbiMed's CBAY Position: Q2 2019 in Review

OrbiMed sold out of Cymabay Therapeutics (CBAY) in Q2 2019, closing a stake of 1,874,955 shares — an estimated $24.9M sold.

OrbiMed first reported a position in CBAY in Q1 2019 and held it in 1 quarter. The position peaked at $24.9M in Q1 2019. 133 funds tracked by Wall St. Rank hold CBAY as of Q2 2019.

OrbiMed reported no remaining Cymabay Therapeutics position as of Q2 2019 after selling out during the quarter.
OrbiMed sold 1,874,955 Cymabay Therapeutics shares in Q2 2019, an estimated $24.9M.
OrbiMed first reported a position in Cymabay Therapeutics in Q1 2019 and held it in 1 quarter.
OrbiMed's Cymabay Therapeutics position peaked at $24.9M in Q1 2019.
133 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2019.

Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.